Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration: Magnetic Resonance Imaging Study in an Experimental Model of Atherosclerosis

Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano(ETC-216) Administration: Magnetic Resonance Imaging Study in an Experimental Model of Atherosclerosis Borja Ibanez, Gemma Vilahur, Giovanni Cimmino, Walter S. Speidl, Antonio Pinero, Brian G....

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2008-03, Vol.51 (11), p.1104
Main Authors: Ibanez, Borja, Vilahur, Gemma, Cimmino, Giovan ni, Speidl, Walter S, Pinero, Antonio, Choi, Brian G, Zafar, M Urooj, Santos-Gallego, Carlos G, Krause, Brian, Badimon, Lina, Fuster, Valentin, Badimon, Juan J
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Apolipoproteins
Atherosclerosis
Cardiology
Cholesterol
Laboratory animals
Lipids
Methods
NMR
Nuclear magnetic resonance
Proteins
Rodents
Smooth muscle
Statins
Statistical analysis
Studies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano(ETC-216) Administration: Magnetic Resonance Imaging Study in an Experimental Model of Atherosclerosis Borja Ibanez, Gemma Vilahur, Giovanni Cimmino, Walter S. Speidl, Antonio Pinero, Brian G. Choi, M. Urooj Zafar, Carlos G. Santos-Gallego, Brian Krause, Lina Badimon, Valentin Fuster, Juan J. Badimon In this experimental study, serial magnetic resonance imaging evaluations of atherosclerotic plaques showed that short-term treatment (4 days) with recombinant apolipoprotein (apo) A-IMilanoinduced a significant plaque regression. We further show that the rapid atherosclerotic regression was accompanied by a profound change in the composition and activity of the lesions. The apoA-IMilanoinfusion not only reduced by 50% the density of macrophages within the plaques, but also promoted a down-regulation of markers frequently associated with plaque vulnerability. The ApoA-IMilanorepresents a promising intervention to be tested in future clinical trials on high-risk patients.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2007.09.071